Comparison 10. Pimecrolimus 1.0% BID vs. tacrolimus 0.1% BID.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Clear or almost clear eczema (IGA 0 or 1)	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
1.1 1 week	2	639	Risk Ratio (M‐H, Random, 95% CI)	0.85 [0.53, 1.34]
1.2 3 weeks	2	639	Risk Ratio (M‐H, Random, 95% CI)	0.56 [0.41, 0.77]
1.3 6 weeks	2	639	Risk Ratio (M‐H, Random, 95% CI)	0.58 [0.46, 0.74]
2 Withdrawals	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
2.1 For any reason	2	639	Risk Ratio (M‐H, Random, 95% CI)	1.18 [0.91, 1.52]
2.2 For lack of efficacy	2	639	Risk Ratio (M‐H, Random, 95% CI)	2.37 [1.10, 5.08]
2.3 For adverse events	2	639	Risk Ratio (M‐H, Random, 95% CI)	1.01 [0.43, 2.41]
3 Adverse events	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
3.1 Any adverse events	2	639	Risk Ratio (M‐H, Random, 95% CI)	1.04 [0.47, 2.26]
3.2 Skin infections	2	639	Risk Ratio (M‐H, Random, 95% CI)	1.60 [0.37, 6.99]
3.3 Viral skin infections	1	413	Risk Ratio (M‐H, Random, 95% CI)	1.03 [0.07, 16.43]
3.4 Application site skin burning	2	639	Risk Ratio (M‐H, Random, 95% CI)	0.76 [0.36, 1.62]